PDS Biotechnology (PDSB) Competitors $1.16 0.00 (0.00%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.16 0.00 (-0.43%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDSB vs. AVTE, OGI, TNYA, SOPH, CRGX, RAPT, TIL, TRDA, SLS, and HRTXShould you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Aerovate Therapeutics (AVTE), Organigram Global (OGI), Tenaya Therapeutics (TNYA), SOPHiA GENETICS (SOPH), CARGO Therapeutics (CRGX), Rapt Therapeutics (RAPT), Instil Bio (TIL), Entrada Therapeutics (TRDA), SELLAS Life Sciences Group (SLS), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. PDS Biotechnology vs. Its Competitors Aerovate Therapeutics Organigram Global Tenaya Therapeutics SOPHiA GENETICS CARGO Therapeutics Rapt Therapeutics Instil Bio Entrada Therapeutics SELLAS Life Sciences Group Heron Therapeutics Aerovate Therapeutics (NASDAQ:AVTE) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations. Which has more volatility & risk, AVTE or PDSB? Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Do institutionals and insiders believe in AVTE or PDSB? 26.8% of PDS Biotechnology shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, AVTE or PDSB? Aerovate Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.53PDS BiotechnologyN/AN/A-$37.61M-$0.92-1.26 Do analysts rate AVTE or PDSB? PDS Biotechnology has a consensus target price of $10.00, indicating a potential upside of 762.07%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AVTE or PDSB more profitable? Aerovate Therapeutics' return on equity of -90.19% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% PDS Biotechnology N/A -184.56%-79.00% Does the media favor AVTE or PDSB? In the previous week, Aerovate Therapeutics and Aerovate Therapeutics both had 1 articles in the media. PDS Biotechnology's average media sentiment score of 1.91 beat Aerovate Therapeutics' score of 1.68 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Aerovate Therapeutics Very Positive PDS Biotechnology Very Positive SummaryPDS Biotechnology beats Aerovate Therapeutics on 9 of the 12 factors compared between the two stocks. Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition Export to ExcelMetricPDS BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.55M$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-1.2621.2475.1126.39Price / SalesN/A431.67511.76177.24Price / CashN/A44.4425.8129.91Price / Book2.279.6413.456.28Net Income-$37.61M-$53.20M$3.29B$270.38M7 Day Performance-1.69%0.07%0.08%1.89%1 Month Performance-2.52%4.27%4.59%6.01%1 Year Performance-62.09%9.62%75.30%25.26% PDS Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology2.3464 of 5 stars$1.16flat$10.00+762.1%-61.3%$54.55MN/A-1.2620AVTEAerovate TherapeuticsN/A$7.77-0.1%N/A-88.4%$225.21MN/A-2.6020Positive NewsHigh Trading VolumeOGIOrganigram Global1.1075 of 5 stars$1.64-0.6%N/A-8.1%$221.18M$117.47M32.81860TNYATenaya Therapeutics3.1694 of 5 stars$1.40+3.7%$6.25+346.4%-40.0%$220.02MN/A-1.46110Positive NewsSOPHSOPHiA GENETICS1.8052 of 5 stars$3.32+2.5%$8.00+141.0%-20.9%$218.96M$65.17M-7.55520CRGXCARGO Therapeutics1.6611 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116News CoverageRAPTRapt Therapeutics4.2119 of 5 stars$13.28+2.7%$21.57+62.4%+11.7%$213.83M$1.53M-0.9480News CoverageAnalyst UpgradeTILInstil Bio2.8464 of 5 stars$25.77-18.2%$119.00+361.8%-69.5%$212.65MN/A-1.99410Gap DownHigh Trading VolumeTRDAEntrada Therapeutics2.5389 of 5 stars$5.28-0.2%$25.67+386.1%-66.3%$201.22M$210.78M-2.97110SLSSELLAS Life Sciences Group1.3689 of 5 stars$1.90-0.5%$7.00+268.4%+27.3%$201.12M$1M-5.9410HRTXHeron Therapeutics4.1494 of 5 stars$1.30-0.8%$4.50+246.2%-33.7%$200.81M$144.29M-65.00300Positive News Related Companies and Tools Related Companies AVTE Competitors OGI Competitors TNYA Competitors SOPH Competitors CRGX Competitors RAPT Competitors TIL Competitors TRDA Competitors SLS Competitors HRTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PDSB) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PDSB Stock Alerts